InvestorNewsBreaks

Wednesday Mar 26, 2025 - 10:35 am

InvestorNewsBreaks – Tesla Inc. (NASDAQ: TSLA) Stock Rises for Fifth Consecutive Session Amid Analyst Optimism

Tesla (NASDAQ: TSLA) has achieved its fifth consecutive day of stock gains, closing at $288.14 on Tuesday, March 25, 2025. This 3.5% increase brings the stock up 28% over the past five days, reversing a two-month decline. The rally comes despite reports of falling sales in the European Union for the second consecutive month. Analysts attribute the surge to CEO Elon Musk's encouragement for employees…

Wednesday Mar 26, 2025 - 9:39 am

InvestorNewsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Reports Record Revenue Surge Driven by Commercial EV Sales

Mullen Automotive (NASDAQ: MULN) announced record GAAP revenue of $3.18 million as of March 21, 2025, marking a 189% increase over its total 2024 revenue of $1.1 million. The surge reflects strong momentum in sales of its commercial EVs, including the Mullen ONE cargo van and Mullen THREE cab chassis truck, both of which are fully certified under U.S. emissions and safety standards. The company…

Wednesday Mar 26, 2025 - 9:28 am

InvestorNewsBreaks – Thumzup Media Corp. (NASDAQ: TZUP) Unveils Lifestyle AI Agent Marketplace and Files Trademarks for GibberAds

Thumzup (NASDAQ: TZUP) announced the development of its patent-pending Lifestyle AI Agent Marketplace, a next-gen platform designed to deliver hyper-personalized experiences using specialized AI agents. The system will feature premium AI "swarms" that collaborate to create lifestyle plans in areas like travel, wellness, and entertainment, while offering real-time promotions to users from participating businesses. Thumzup also filed trademark applications for its AI-powered marketing tools, Gibberlink…

Wednesday Mar 26, 2025 - 9:25 am

InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Reports Encouraging Progress in Brain Cancer Trial with City of Hope

Calidi Biotherapeutics (NYSE American: CLDI) announced promising early results from a phase 1 clinical trial evaluating its CLD-101 investigational agent, a neural stem cell-based oncolytic virotherapy, in collaboration with City of Hope. The trial, targeting recurrent high-grade glioma, is the first to assess multiple weekly intracerebral doses of CLD-101. Fourteen participants have been treated so far with no safety concerns, and the study is now…

Wednesday Mar 26, 2025 - 9:25 am

InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Begins Final Preclinical Study for PTSD Treatment SPC-15

Silo Pharma (NASDAQ: SILO) announced the first dosing in a GLP-compliant toxicology and toxicokinetics study for its lead candidate, SPC-15, an intranasal treatment for post-traumatic stress disorder (PTSD). The study, part of an IND-enabling program, follows a pre-IND meeting with the FDA that aligned the company on the 505(b)(2) regulatory pathway, which may expedite approval and reduce development costs. SPC-15, a serotonin 5-HT4 receptor agonist…

Wednesday Mar 26, 2025 - 9:10 am

InvestorNewsBreaks – Standard Lithium Ltd. (NYSE American: SLI) Advances Key Projects in Arkansas and East Texas

Standard Lithium (NYSE American: SLI) announced a corporate update highlighting continued progress on its lithium development initiatives, including the start of a dual-track project finance and off-take process for its South West Arkansas Project. The process, launched in January, aims to support the project’s first phase, targeting 22,500 tonnes per year of battery-quality lithium carbonate production. In East Texas, the company’s joint venture with Equinor…

Wednesday Mar 26, 2025 - 9:00 am

InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Launches Retail-Ready unbuzzd Stick Packs Across U.S. Stores

Quantum BioPharma (NASDAQ: QNTM) announced that its licensee Celly Nutrition Corporation has introduced a new format of its unbuzzd™ beverage supplement—“On-the-Go Powder Stick Packs”—now sold in 8-pack display boxes. Designed for convenience and portability, the new packaging supports broader retail distribution in convenience, liquor, and drug stores across the United States. The product, which accelerates alcohol metabolism and reduces hangover symptoms, is also available online in…

Tuesday Mar 25, 2025 - 2:00 pm

InvestorNewsBreaks – Adageis Is Bringing AI to the Forefront of Value-Based Care

Adageis, a leading healthcare technology company, is at the forefront of an industry shift as providers increasingly prioritize specific, high-impact artificial intelligence (“AI”) applications that enhance patient care and financial performance. The company was featured in a recent article that discussed its innovative AI-driven solutions through its ProActive Care Platform, which offers practical applications that directly impact revenue generation and patient care. Adageis’ AI solutions…

Tuesday Mar 25, 2025 - 1:14 pm

InvestorNewsBreaks – MoneyShow Event to Spotlight Insights for Navigating 2025 Market Dynamics

MoneyShow, a premier producer of financial conferences for affluent investors, active traders, and financial advisors, has announced the return of Outlook 2025: Big Market Trends, Bold Investment Ideas. The two-day event, set to take place at the Hilton DFW Lakes in Dallas on Apr. 4-5, 2025, will provide actionable insights for navigating the opportunities and challenges of the new year. “Following the inauguration of President…

Tuesday Mar 25, 2025 - 10:57 am

InvestorNewsBreaks – SolarBank Corp. (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) Closes $8.5 Million Direct Offering with Institutional Investor

Disseminated on behalf of SolarBank Corporation SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) has closed a registered direct offering with a single institutional investor, securing approximately $8.5 million in gross proceeds. The investor, backed by a bulge bracket investment bank and active in the energy sector, purchased 2,394,367 common shares and an equal number of warrants at a combined price of $3.55 per share.…

Tuesday Mar 25, 2025 - 10:07 am

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Phase 2 Results for Berubicin in Glioblastoma Trial

CNS Pharmaceuticals (NASDAQ: CNSP) announced results from its Phase 2 clinical trial evaluating Berubicin for recurrent or progressive Glioblastoma Multiforme (GBM). While the study did not meet its primary endpoint of statistically significant improvement in overall survival compared to standard-of-care Lomustine, Berubicin showed comparable results across key clinical outcomes, including in patients with poor tumor markers. Importantly, no cardiotoxicity was observed, a major concern with…

Tuesday Mar 25, 2025 - 10:00 am

InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) to Present Late-Stage Alzheimer’s and Parkinson’s Data at AD/PD 2025

Annovis Bio (NYSE: ANVS), a clinical-stage drug platform company focused on neurodegenerative diseases, will present key data from its Phase 3 Parkinson’s and Phase 2/3 Alzheimer’s studies at the AD/PD™ 2025 conference in Vienna from April 1–5. Presentations will highlight buntanetap’s impact on cognition and motor function in early Parkinson’s patients, and its advantages for APOE4 carriers in Alzheimer’s disease. Annovis CEO Maria Maccecchini and…

Tuesday Mar 25, 2025 - 9:56 am

InvestorNewsBreaks – SKYX Platforms Corp. (NASDAQ: SKYX) Reports 48% Revenue Growth in 2024, Eyes Profitability in Second Half of 2025

SKYX Platforms (NASDAQ: SKYX) reported a 48% year-over-year revenue increase, reaching $86.3 million in 2024, including a record $23.7 million in fourth-quarter sales. The company narrowed its net loss to $0.36 per share, improved gross profit to $24.6 million, and reduced general and administrative expenses by $5.7 million. SKYX ended the year with $15.5 million in cash and secured an additional $1.45 million in March…

Tuesday Mar 25, 2025 - 9:30 am

InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Present at Jones Las Vegas Technology and Innovation Conference

Clene (NASDAQ: CLNN), a clinical-stage biopharmaceutical company advancing treatments for neurodegenerative diseases such as ALS and MS, will participate in the Jones Las Vegas Technology and Innovation Conference on April 8–9, 2025. Held at The Venetian Resort, the event will feature one-on-one meetings, panels, and networking with institutional investors. Clene CEO Rob Etherington will represent the company as it continues to highlight progress across its therapeutic…

Tuesday Mar 25, 2025 - 9:20 am

InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Taps IBN to Lead Corporate Communications Strategy

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company targeting rare diseases, has selected IBN to manage its corporate communications and investor outreach. Soligenix is advancing late-stage clinical programs through its oncology and inflammation-focused Specialized BioTherapeutics segment and its Public Health Solutions division, which develops vaccines for biothreats such as ricin, Ebola, and Marburg. With support from roughly $60 million in non-dilutive funding and a pipeline that…

Tuesday Mar 25, 2025 - 9:16 am

InvestorNewsBreaks – Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) Hosts Investor Call Highlighting Actimab-A Clinical Progress and Expansion into Solid Tumors

Actinium Pharmaceuticals (NYSE AMERICAN: ATNM), a leader in targeted radiotherapies, will hold an investor call today at 8:00 a.m. ET featuring Dr. Ehab Atallah, Professor of Medicine at the Medical College of Wisconsin and principal investigator of the Actimab-A + CLAG-M trial for relapsed/refractory acute myeloid leukemia (r/r AML). Dr. Atallah will present updated clinical results, including long-term survival data and plans for a pivotal…

Tuesday Mar 25, 2025 - 9:15 am

InvestorNewsBreaks – Datavault AI Inc. (NASDAQ: DVLT) Partners with NYIAX to Launch Ultrasonic Advertising Platform

Datavault AI (NASDAQ: DVLT), a leader in AI-driven data monetization, has signed a strategic licensing agreement with NYIAX to integrate its patented ADIO® technology into NYIAX’s Nasdaq-powered advertising exchange. This collaboration will enable one of the world’s first ultrasonic advertising platforms, delivering inaudible data through sound to consumers in stadiums, retail locations, and across broadcasts. The integration is expected to complete in Q2 2025, with…

Tuesday Mar 25, 2025 - 9:00 am

InvestorNewsBreaks – Centri Capital Conference to Showcase the Future of Capital Markets

Centri Business Consulting, LLC, one of the industry's fastest-growing and most respected accounting and advisory firms, is set to host its Centri Capital Conference. Slated to take place at Nasdaq in New York City on April 22, the event will bring together key players from the capital markets ecosystem, including investment bankers, private equity investors and venture capitalists. The conference will feature dynamic presentations from…

Monday Mar 24, 2025 - 9:44 am

InvestorNewsBreaks – Standard Lithium Ltd. (NYSE American: SLI) Advances Toward Final Investment Decision With $225M DOE Grant

Standard Lithium (NYSE American: SLI), a near-commercial lithium company, reported financial and operational results for the six-month period ended Dec. 31, 2024, highlighting key milestones toward its South West Arkansas project. The company finalized a $225 million grant from the U.S. Department of Energy to support Phase 1 construction and completed successful pilot testing with over 99% lithium recovery. With FEED and DFS nearing completion…

Monday Mar 24, 2025 - 9:40 am

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Subsidiary Pearsanta Acquires Patents for DNA Damage Detection in Cancer Prevention

Aditxt (NASDAQ: ADTX) announced that its subsidiary, Pearsanta, Inc., has acquired key patents for adductomics-based DNA damage detection in a $1 million stock transaction. The move expands Pearsanta’s capabilities in early cancer risk assessment, complementing its existing Mitomic® Technology. The acquired technology detects DNA adducts—early markers of carcinogen exposure—allowing for potential cancer prevention strategies before permanent mutations develop. Pearsanta plans to advance clinical validation and…

Monday Mar 24, 2025 - 9:36 am

InvestorNewsBreaks – Datavault AI Inc. (NASDAQ: DVLT) Joins IBM Partner Plus Program to Scale AI Data Monetization

Datavault AI (NASDAQ: DVLT), a leader in AI-powered data valuation and monetization, announced its inclusion in IBM’s Partner Plus program, joining a global network of 500 partners. The company will integrate IBM watsonx™ tools into its AI agents—Data Vault Bank®, DataScore® and DataValue®—to advance secure, compliant enterprise data monetization. Datavault AI also completed integration with identity partner CLEAR and expanded its strategic alliance with NYIAX.…

Monday Mar 24, 2025 - 9:33 am

InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Plans 2025 NDA Submission Following Positive ALS Trial Data

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company, reported a full-year 2024 net loss of $39.4 million, or $5.67 per share, compared to a loss of $49.5 million in 2023. Revenue remained limited, but Clene highlighted regulatory progress and survival data supporting CNM-Au8, its gold nanocrystal suspension for ALS. The company expects to meet with the FDA in Q2 2025 to finalize analysis plans for biomarker…

Monday Mar 24, 2025 - 9:30 am

InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Advances Fibromyalgia Drug Without Advisory Committee Review

Tonix Pharmaceuticals (NASDAQ: TNXP), a biopharmaceutical company with marketed products and a robust development pipeline, announced that the FDA will not require an Advisory Committee meeting to evaluate its New Drug Application for TNX-102 SL, a potential new treatment for fibromyalgia. If approved, TNX-102 SL would be the first new fibromyalgia therapy in 15 years. The drug, which previously received Fast Track designation, could launch…

Monday Mar 24, 2025 - 9:20 am

InvestorNewsBreaks – Brera Holdings PLC (NASDAQ: BREA) Highlights Juve Stabia Academy as Key Youth Football Investment

Brera Holdings (NASDAQ: BREA), an Ireland-based international holding company focused on multi-club ownership, spotlighted the Juve Stabia Academy for its role in developing elite football talent in the Naples Metropolitan Area. The investment reflects Brera’s strategy to support grassroots football and create a global network of academies. Juve Stabia has a history of producing top-tier talent, including Luigi Vitale and Antonio Donnarumma, and aligns with…

Monday Mar 24, 2025 - 9:12 am

InvestorNewsBreaks – Thumzup Media Corp. (NASDAQ: TZUP) Reports Insider Stock Purchases and Accelerated Buybacks

Thumzup (NASDAQ: TZUP), an emerging player in social media branding and programmatic marketing, reported that company insiders acquired approximately $60,381 in common stock during the March 2025 trading window, following $62,000 in purchases in Dec. 2024. Cumulatively, insiders have invested over $740,000 in the company since inception. Thumzup also repurchased about $216,000 worth of stock in the past three trading days under its $1 million…

Monday Mar 24, 2025 - 9:10 am

InvestorNewsBreaks – HealthLynked Corp. Enhances Booking Platform and ARi Voice Assistant

HealthLynked (OTCQB: HLYK), a global healthcare network focused on improving patient care, announced updates to its in-office online appointment booking system and enhancements to its ARi voice assistant. New scheduling features include next-available or specific-day requests, flexible time-of-day preferences, and the ability to submit provider reviews without logging in. Upgrades to ARi include improved background noise filtering and smarter response detection, designed to boost reliability…

Monday Mar 24, 2025 - 9:09 am

InvestorNewsBreaks – Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) Secures Actinium-225 Supply Agreement with Eckert & Ziegler to Support Expanding Pipeline

Actinium Pharmaceuticals (NYSE AMERICAN: ATNM), a leader in targeted radiotherapies, announced a supply agreement with Eckert & Ziegler for Actinium-225 (Ac-225) to support development of its lead candidate Actimab-A and other radiotherapy programs. The agreement ensures access to high-quality Ac-225 for both U.S. and international clinical trials. Actimab-A, an Ac-225-based agent targeting CD33, is being advanced into pivotal Phase 2/3 trials for relapsed/refractory acute myeloid…

Monday Mar 24, 2025 - 9:00 am

InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Advances Alzheimer’s and Parkinson’s Pipeline, Launches Pivotal Phase 3 Trial

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company, reported fourth quarter and full year 2024 results, highlighting major milestones in its buntanetap program for Alzheimer’s and Parkinson’s disease. The company completed two key trials last year, showing cognitive and motor improvements, leading to FDA clearance for a pivotal Phase 3 trial in early Alzheimer’s, which began in early 2025. Annovis also expanded its…

Friday Mar 21, 2025 - 3:10 pm

InvestorNewsBreaks – Upstream at the Forefront of the Shift Toward Expanded Trading

Upstream published a blog today that discussed challenges faced by legacy stock exchanges transitioning to 24/5 trading, outlining obstacles such as outdated infrastructure, regulatory hurdles, operational constraints for brokers and clearing firms, liquidity fragmentation, and cybersecurity risks. Significant upgrades are needed for traditional exchanges to support real-time settlement and extended trading hours. On the other hand, blockchain-powered platforms like Upstream are designed to overcome these…

Friday Mar 21, 2025 - 1:48 pm

InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI): Poised in the Future of Oncology with Cutting-Edge Treatments

Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage biotechnology company at the forefront of research and development of innovative treatments in the field of immuno-oncology. With cancer being the second leading cause of death globally, the company focuses on harnessing antitumor virotherapies and patented technologies designed to protect and potentiate the virotherapy during administration to combat cancer more effectively and with fewer side effects. The…

Friday Mar 21, 2025 - 12:30 pm

InvestorNewsBreaks – TC BioPharm Holdings PLC (NASDAQ: TCBP) to Be Delisted, Will Move to OTC Markets

TC BioPharm (NASDAQ: TCBP), a clinical-stage biotech company focused on allogeneic gamma-delta T cell therapies, announced it will be delisted from the Nasdaq Stock Market following a determination by the Nasdaq Hearings Panel. The decision, dated March 20, 2025, stems from the company's failure to meet the minimum $1.00 bid price required under Rule 5550(a)(2). Trading on Nasdaq will be suspended at the opening on…

Friday Mar 21, 2025 - 12:20 pm

InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Unveils Progress on CNM-Au8(R), Eyes Potential Fast-Track FDA Approval

Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), is actively advancing its lead drug candidate, CNM-Au8®. The company presented its progress at two key investor events this month, including the Q1 Virtual Investor Summit and…

Friday Mar 21, 2025 - 11:50 am

InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Announces Key Milestones and 2024 Financial Results

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today announced its recent accomplishments and financial results for the year ended Dec. 31, 2024. “We remain highly focused on advancing our multiple clinical programs as we work towards achieving a number of important and potentially transformational development milestones, including top-line…

Friday Mar 21, 2025 - 10:03 am

InvestorNewsBreaks – General Mills, Inc. (NYSE: GIS) Reports Mixed Q3 2025 Results, Updates Outlook

General Mills (NYSE: GIS) announced its third-quarter fiscal 2025 results, reporting earnings per share (“EPS”) of $1.00, surpassing analyst expectations of $0.98. However, revenue fell short, totaling $4.8 billion against a projected $4.99 billion. The company attributed the revenue miss to greater-than-expected retailer inventory headwinds and a slowdown in U.S. snacking categories. In response, General Mills plans to invest in consumer value, media support, and…

Friday Mar 21, 2025 - 9:25 am

InvestorNewsBreaks – McEwen Mining Inc. (NYSE: MUX) (TSX: MUX) Backs Goliath Resources Through Warrant Exercise Participation

McEwen Mining (NYSE: MUX) (TSX: MUX) through its founder Rob McEwen, has reaffirmed confidence in Goliath Resources (TSX-V: GOT) (OTCQB: GOTRF) by participating in recent warrant exercises, contributing to the $3.2 million Goliath has received since Jan. 1. McEwen, who holds approximately 3.9% of Goliath’s shares, joins Crescat Capital (~14.4%) in leveraging deep-in-the-money warrants ahead of key expiration dates in 2025. This influx of capital…

Friday Mar 21, 2025 - 9:24 am

InvestorNewsBreaks – D-Wave Quantum Inc. (NYSE: QBTS) Unveils Quantum-Powered Blockchain Architecture

D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software, and services, has introduced a novel blockchain architecture that incorporates quantum computing techniques to enhance security and efficiency. The company’s new research paper, Blockchain with Proof of Quantum Work, details how a “proof of quantum” algorithm utilizes quantum computation to generate and validate blockchain hashes. D-Wave deployed this architecture across four of…

Thursday Mar 20, 2025 - 1:28 pm

InvestorNewsBreaks – Thumzup Media Corp. (NASDAQ: TZUP) Repurchases $126,507 in Common Stock

Thumzup (NASDAQ: TZUP), a growing force in social media branding and programmatic marketing, announced the repurchase of $126,507 of its common stock as part of its previously approved $1 million buyback program. The company views the repurchase as a strategic move to enhance shareholder value and reinforce confidence in its growth trajectory. CEO Robert Steele highlighted the buyback as a demonstration of Thumzup's commitment to…

Thursday Mar 20, 2025 - 11:20 am

InvestorNewsBreaks – NVIDIA Corp. (NASDAQ: NVDA) Commits to U.S. Manufacturing Amid AI Industry Growth

NVIDIA (NASDAQ: NVDA) plans to invest hundreds of billions of dollars in U.S. chip manufacturing over the next four years, aligning with President Donald Trump's initiatives to bolster the artificial intelligence (“AI”) industry and domestic production. CEO Jensen Huang praised the administration's support, stating it creates "phenomenal" opportunities for AI development in the U.S. As of 10:32 AM EDT on March 20, 2025, Nvidia's…

Thursday Mar 20, 2025 - 11:14 am

InvestorNewsBreaks – Hello Group Inc. (NASDAQ: MOMO) Upgraded to ‘Buy’ by Huatai Securities With $11.69 Target

Hello Group (NASDAQ: MOMO), received an upgrade from Huatai Securities, which raised the stock's rating to "Buy" and set a target price of $11.69. The firm cited the company's strong user engagement and revenue growth potential as key factors in its revised outlook. Hello Group, known for its Momo and Tantan social networking platforms, continues to expand its influence in China's online dating and social…

Thursday Mar 20, 2025 - 11:00 am

InvestorNewsBreaks – Apple Inc. (NASDAQ: AAPL) Loses Top Health Executive to Oura, Fueling Smart Ring Market Growth

Apple (NASDAQ: AAPL) has lost a key executive from its health division, as Dr. Ricky Bloomfield, formerly the Clinical and Health Informatics Lead, departs to join Oura as its Chief Medical Officer. Bloomfield played a critical role in shaping Apple's health strategy, including its push into digital health records and wearable health tracking. His move to Oura, a company specializing in smart rings for health…

InvestorNewsBreaks

Get Started with InvestorWire

Press Distribution

Explore Press Distribution Solutions

Discover Add-on Solutions